Skip to content

About
Pipeline
News
Contact

News

Press Releases
Publications

Stelexis Therapeutics Closes $43 million Series A to Expand Novel Platform Focused on Cancer Interception

27th January 2019

Eradicating hematological cancers at their root causes

Follow Us

© 2026 Stelexis. Terms. Privacy.